DSGN shares soared 8% today. A look at what's happening:

Design Therapeutics, Inc. (DSGN) is trading 8% higher at $21.85 today. Shares of the stock are quickly outrunning other names in the space on what is turning out to be a slightly bearish day for the Health Care sector.

Some possible catalysts:
-The initial data from the Friedreich Ataxia Phase 1 trial of DT-216 is expected in the fourth quarter of 2022.
-This trial is looking to see if DT-216 can help improve the symptoms of Friedreich Ataxia.

Design Therapeutics, Inc. has been trading between a 52-week high of $26.3 and a 52-week low of $9.61. The stock has a market cap of $1.22 Billion.

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.